Search clinical trials for: Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine

Total 212 results

Xiamen Ophthalmology Center Affiliated to Xiamen...
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Active, not recruiting

An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old

Cervical Cancer | Condylomata Acuminata

China
Xiamen University
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Completed

Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age

Cervical Cancer | Condylomata Acuminata

China
Xiamen University
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Not yet recruiting

Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women

Cervical Cancer | Condylomata Acuminata

China
Beijing Health Guard Biotechnology, Inc
National Institutes for Food and Drug Control, China; Jiangsu Province Centers... and other collaborators

Completed

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Human Papillomavirus Infection

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Allogeneic Hematopoietic Stem Cell Transplant Recipient

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Evandro Chagas National Institute of Infectious... and other collaborators

Active, not recruiting

Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial (OPTIMO)

HIV Infection

Peru, Brazil, Haiti
National Cancer Institute (NCI)

Active, not recruiting

Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants

Human Papillomavirus-Related Carcinoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

High Grade Anal Canal Intraepithelial Neoplasia | High Grade Vulvar Squamous Intraepithelial Lesion

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of California, Los Angeles; Merck... and other collaborators

Active, not recruiting

HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV (COVENANT)

HIV Infection | AIDS-Related Human Papillomavirus Infection | High Grade Cervical Squamous Intraepithelial Neoplasia

Uganda, Kenya, Zimbabwe, South Africa, Malawi
National Cancer Institute (NCI)
Bill and Melinda Gates Foundation

Enrolling by invitation

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study (ESCUDDO)

Human Papillomavirus Infection | Human Papillomavirus-Related Cervical Carcinoma

Costa Rica
National Cancer Institute (NCI)

Active, not recruiting

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

Human Papillomavirus Infection

United States
National Cancer Institute (NCI)

Active, not recruiting

Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial

Human Papillomavirus-Related Cervical Carcinoma

Costa Rica
National Cancer Institute (NCI)

Active, not recruiting

Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PRISMA)

Cervical Carcinoma | Human Papillomavirus Infection

Costa Rica
Beijing Health Guard Biotechnology, Inc

Active, not recruiting

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Human Papillomavirus Infection

China
Beijing Health Guard Biotechnology, Inc
National Institutes for Food and Drug Control, China; Jiangsu Province Centers... and other collaborators

Completed

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

Human Papilloma Virus Infection

China
Beijing Health Guard Biotechnology, Inc
University of Muhammadiyah Malang Hospital; Dr. M Djamil Hospital, Padang

Active, not recruiting

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Human Papillomavirus Infection

Indonesia
University of California, San Francisco

Recruiting

Intralesional HPV Vaccine for Condylomata

Warts | Condylomata Acuminata | Human Papilloma Virus | Warts, Genital | Condyloma

United States
Beijing Health Guard Biotechnology, Inc
National Institutes for Food and Drug Control, China; Yunnan Center for Disease... and other collaborators

Active, not recruiting

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Human Papillomavirus Infection

China
National Cancer Institute (NCI)

Not yet recruiting

Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

Human Papillomavirus-Related Carcinoma

United States, Austria
Zagazig University

Completed

Gardasil Versus Cervarix in the Treatment of Warts

Verruca Viral

Egypt
University of Washington
Merck Sharp & Dohme LLC

Completed

Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents

HPV Infection | HPV Vaccination

Kenya
Washington University School of Medicine

Completed

The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata

HIV Infections | HIV Positive | Anal Condylomata | Anal Warts

United States
Merck Sharp & Dohme LLC

Suspended

Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)

HPV Infections
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)

Papillomavirus Infections
Universidad Nacional Autonoma de Mexico
Merck Sharp & Dohme LLC; Secretaria de Salud, Mexico

Unknown

Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City

Human Papilloma Virus

Mexico
University of Alabama at Birmingham
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

Cancer Survivor | Prevention of Human Papillomavirus Infection

United States
Merck Sharp & Dohme LLC

Completed

An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)

HPV Infections
PATH
National Institute of Hygiene and Epidemiology, Vietnam

Completed

Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil

Dose Schedule Study

Vietnam
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)

Prevention | Papillomavirus Infection | Healthy Adult Female Participants | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
Shanghai Zerun Biotechnology Co.,Ltd
Yuxi Zerun Biotechnology Co., Ltd.

Completed

Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females

HPV Infection

China
AIDS Malignancy Consortium
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; University of Arkansas and other collaborators

Completed

Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

Precancerous Condition | Anal Cancer | Penile Cancer | Nonneoplastic Condition

United States, Puerto Rico
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC

Completed

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

Infection | Precancerous Condition

United States
Merck Sharp & Dohme LLC

Completed

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Papillomavirus Infections
University Hospital Virgen de las Nieves
Instituto de Salud Carlos III

Unknown

Immunogenicity and Safety of a 9-valent Human Papillomavirus Vaccine in HIV-positive Women (9-VPH-MVIH)

HIV Infections | HPV Infection

Spain
Merck Sharp & Dohme LLC

Completed

V501 Efficacy Study in Women Aged 18 to 26 (V501-027)

HPV Infections
Sinocelltech Ltd.

Recruiting

A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years

HPV Infection Vaccine Safety SCT1000

China
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)

Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ

China
Shanghai Bovax Biotechnology Co., Ltd.

Terminated

A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

Cervical Cancer | CIN1 | CIN2 | CIN3 | Genital Wart | AIS | Vain I | Vain III | Vin I | Vin II | Vin III | VAIN - Vaginal Intraepithelial Neoplasia 2

China
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®

Dengue Fever | Dengue Hemorrhagic Fever | Human Papillomavirus Disease

Mexico
Merck Sharp & Dohme LLC

Active, not recruiting

Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015) (FUTURE II)

Cervical Cancer | Genital Warts
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts
Merck Sharp & Dohme LLC

Completed

Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)

Cervical Cancer | Genital Warts
Xiamen University
Xiamen Innovax Biotech Co., Ltd; Center for Disease Control and Prevention,...

Not yet recruiting

Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls

Cervical Cancer | Cervical Intraepithelial Neoplasia | Persistent Infection

China
University of British Columbia
Merck Canada Inc.

Completed

Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine (Merck08)

Human Papillomavirus

Canada
Merck Sharp & Dohme LLC

Completed

Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)

Neoplasms, Glandular and Epithelial | Whooping Cough | Tetanus | Diphtheria | Poliomyelitis
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®

Dengue Fever | Dengue Hemorrhagic Fever | Human Papillomavirus Disease

Malaysia
Merck Sharp & Dohme LLC

Completed

Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)

HPV Infections
Merck Sharp & Dohme LLC

Completed

An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)

Condylomata Acuminata
Merck Sharp & Dohme LLC

Completed

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

HPV Infections
Louisiana State University Health Sciences Center...
Merck Sharp & Dohme LLC

Recruiting

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV (AGO-Gard)

Cervical Intraepithelial Neoplasia | Human Immunodeficiency Virus | Anal Intraepithelial Neoplasia | Papillomavirus Infection | Papillomavirus Vaccines | Serology | Oral Cavity Infection

United States

Search clinical trials for: Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations